Insulet PODD
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Insulet (PODD) Business Model and Operations Summary
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.
Key Insights
Insulet (PODD) Core Market Data and Business Metrics
Latest Closing Price
$263.18Market Cap
$18.46 BillionPrice-Earnings Ratio
44.83Total Outstanding Shares
70.23 Million SharesTotal Employees
3,900Dividend
No dividendIPO Date
May 15, 2007SIC Description
Surgical & Medical Instruments & ApparatusPrimary Exchange
NASDAQHeadquarters
100 Nagog Park, Acton, MA, 01720
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities, Continuing | $-5 Million |
| Net Cash Flow From Operating Activities | $327.80 Million |
| Net Cash Flow, Continuing | $213 Million |
| Net Cash Flow From Operating Activities, Continuing | $327.80 Million |
| Net Cash Flow From Financing Activities | $-5 Million |
| Exchange Gains/Losses | $4.20 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Diluted Average Shares | $77.35 Million |
| Cost Of Revenue | $607.90 Million |
| Operating Income/Loss | $306 Million |
| Income/Loss From Continuing Operations Before Tax | $296.70 Million |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Net Income/Loss Available To Common Stockholders, Basic | $420.90 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $433 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $433 Million |
| Comprehensive Income/Loss Attributable To Parent | $433 Million |
| Other Comprehensive Income/Loss Attributable To Parent | $12.10 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Current Liabilities | $506.20 Million |
| Noncurrent Assets | $1.16 Billion |
| Liabilities | $1.91 Billion |
| Equity | $1.12 Billion |
| Other Current Assets | $1.42 Billion |
| Liabilities And Equity | $3.03 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||